These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26197756)

  • 1. [A Patient with Recurrent Ovarian Cancer Who Was Hypersensitive to Carboplatin Exhibited Complete Response to Gemcitabine and Nedaplatin].
    Asami Y; Kitagawa R; Iiba M; Uenoyama A; Kondo K; Sato N; Tadauchi K; Sugita M; Tsunoda H
    Gan To Kagaku Ryoho; 2015 Jul; 42(7):883-5. PubMed ID: 26197756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
    Micha JP; Goldstein BH; Mattison JA; Bader K; Graham C; Rettenmaier MA; Brown JV; Markman M
    Gynecol Oncol; 2005 Jan; 96(1):132-5. PubMed ID: 15589591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study.
    Papadimitriou CA; Fountzilas G; Aravantinos G; Kalofonos C; Moulopoulos LA; Briassoulis E; Gika D; Dimopoulos MA;
    Gynecol Oncol; 2004 Jan; 92(1):152-9. PubMed ID: 14751151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).
    du Bois A; Belau A; Wagner U; Pfisterer J; Schmalfeldt B; Richter B; Staehle A; Jackisch C; Lueck HJ; Schroeder W; Burges A; Olbricht S; Elser G;
    Gynecol Oncol; 2005 Feb; 96(2):444-51. PubMed ID: 15661234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
    Sufliarsky J; Chovanec J; Svetlovska D; Minarik T; Packan T; Kroslakova D; Lalabova R; Helpianska L; Horvathova D; Sevcik L; Spacek J; Laluha A; Tkacova V; Malec V; Rakicka G; Magdin D; Jancokova I; Dorr A; Stresko M; Habetinek V; Koza I
    Neoplasma; 2009; 56(4):291-7. PubMed ID: 19473054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
    Micha JP; Goldstein BH; Rettenmaier MA; Mattison J; Graham C; Birk CL; Brown JV
    Gynecol Oncol; 2004 Sep; 94(3):719-24. PubMed ID: 15350364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
    Bergamini A; Pisano C; Di Napoli M; Arenare L; Della Pepa C; Tambaro R; Facchini G; Gargiulo P; Rossetti S; Mangili G; Pignata S; Cecere SC
    Gynecol Oncol; 2017 Jan; 144(1):72-76. PubMed ID: 28094039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study.
    Steer CB; Chrystal K; Cheong KA; Galani E; Marx GM; Strickland AH; Yip D; Lofts F; Gallagher C; Thomas H; Harper PG
    Gynecol Oncol; 2006 Nov; 103(2):439-45. PubMed ID: 16643993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
    Pectasides D; Pectasides E; Papaxoinis G; Psyrri A; Pliarchopoulou K; Koumarianou A; Macheras A; Athanasas G; Xiros N; Economopoulos T
    Gynecol Oncol; 2010 Jul; 118(1):52-7. PubMed ID: 20406710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma.
    Kose MF; Sufliarsky J; Beslija S; Saip P; Tulunay G; Krejcy K; Minarik T; Fitzthum E; Hayden A; Melemed A
    Gynecol Oncol; 2005 Feb; 96(2):374-80. PubMed ID: 15661224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
    Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Hanaoka T; Hasegawa K; Fujiwara K
    Int J Gynecol Cancer; 2016 Mar; 26(3):443-8. PubMed ID: 26807640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study.
    Mäenpää JU; Grénman SE; Jalkanen JT; Kuoppala TA; Leminen AO; Puistola US; Vuolo-Merilä PM; Yliskoski MH
    Gynecol Oncol; 2006 Apr; 101(1):114-9. PubMed ID: 16266743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons of the survival time of patients with ovarian cancer adopting post-operative chemotherapy by use of paclitaxel combined with carboplatin or nedaplatin.
    Gao H; Yuan L; Han Y
    World J Surg Oncol; 2016 Jun; 14(1):168. PubMed ID: 27341795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine-carboplatin-paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients.
    Fuso L; Amant F; Neven P; Berteloot P; Vergote I
    Int J Gynecol Cancer; 2006; 16 Suppl 1():60-7. PubMed ID: 16515569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer.
    Pfisterer J; Vergote I; Du Bois A; Eisenhauer E; ; ;
    Int J Gynecol Cancer; 2005; 15 Suppl 1():36-41. PubMed ID: 15839957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103).
    Lindemann K; Beale PJ; Rossi E; Goh JC; Vaughan MM; Tenney ME; Martyn JK; Sommeijer D; Iglesias JL; Kremmidiotis G; Simpson J; Doolin E; Lavranos TC; Leske A; Veillard AS; Espinoza D; Stockler MR; Rischin D;
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):97-105. PubMed ID: 30368585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
    Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM
    Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
    Gordon AN; Teneriello M; Janicek MF; Hines J; Lim PC; Chen MD; Vaccarello L; Homesley HD; McMeekin S; Burkholder TL; Wang Y; Zhao L; Orlando M; Obasaju CK; Gill JF; Tai DF
    Gynecol Oncol; 2011 Dec; 123(3):479-85. PubMed ID: 21978765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning.
    Hensley ML; Correa DD; Thaler H; Wilton A; Venkatraman E; Sabbatini P; Chi DS; Dupont J; Spriggs D; Aghajanian C
    Gynecol Oncol; 2006 Aug; 102(2):270-7. PubMed ID: 16490239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
    Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D
    Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.